Company / R&D Expense
4D Molecular Therapeutics, Inc. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$141.3M
FY2025
5-year range
$53.0M / $141.3M
FY2021-FY2025
Trend
+45.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 5 consecutive years, from $39M in FY2020 to $141M in FY2025.
Based on SEC 10-K filings.
$141M in FY2025 with a 5-year CAGR of +29.6%.
Improved from $80M to $141M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +32.1%
- 5-Year CAGR
- +29.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 4D Molecular Therapeutics, Inc.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +29.6%, indicating consistent growth.
- In FY2025, r&d expense increased 45.5% year-over-year.
- Lowest r&d expense in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $141.3M | +45.5% |
| FY2024 | $97.1M | +21.0% |
| FY2023 | $80.3M | +30.8% |
| FY2022 | $61.4M | +15.7% |
| FY2021 | $53.0M | +37.0% |
| FY2020 | $38.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026